Sirion Biotech GmbH

  • Land: Deutschland

Nachricht vom 27.04.2015 | 16:49

Viral Vector Technologies from Europe directly accessible in Boston



(DGAP-Media / 2015-04-27 / 16:49)

27 April 2015

Viral Vector Technologies from Europe directly accessible in Boston

Munich based SIRION Biotech about to open office and lab in Boston Massachusetts

München, 27 April 2015, another Germany company from within its highly innovative life science industry expands into the North American markets, SIRION Biotech in Munich. The company is a leader in the field of viral vectors.

Viral vectors (or virus vectors) are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. Of particular interest are viral vectors in vaccine development such as tumor treatment vaccines.

The company has gained market positions in German speaking countries, Japan, Korea and Israel. It grows fast at a rate of 40% p.a.. Interestingly, the US remains a challenge despite a common belief that similar cultural heritage and technical curiosity should allow for easy market access. Generating new customers is difficult, despite outstanding quality services. Setting up and managing complex project processes and keeping everyone updated, all these developments occur too far away for the Europe based contact. Despite internet and webinars, a sense of distance remains .

SIRION Biotech has over the last 2 years been recruiting and training binational professionals that are now on their way to Boston to establish a physical presence in the US. Boston has a large local market potential and time difference to Europe is only six hours: project inquiries come in in the afternoon, are being discussed with the Europe HQ first thing in the morning, project proposals and quotes are out with potential clients no later than 24 hours. Service levels realized in Europe can thus be offered to US clients as well.

 

About SIRION Biotech www.SIRION-Biotech.com

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies both for research and clinical studies.

Contact SIRION Biotech USA:
SIRION BIOTECH
Dr. Carl Christel
PO Box 3
Durham, NH 03824
Tel.: +1-(857) 284 1844
eMail: christel@SIRION-Biotech.com
www.SIRION-Biotech.com

 



End of Media Release


Issuer: Sirion Biotech GmbH
Key word(s): Services

2015-04-27 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


349225  2015-04-27 

Interview im Fokus

„Stark positioniert im Wachstumsmarkt für geschlossene Zahlungssysteme“

Digitale Zahlungssysteme für Universitäten, öffentliche Einrichtungen und Events sowie digitale Sicherheitslösungen sind die Kernthemen, mit denen sich die Beteiligungen der SANDPIPER Digital Payments AG befassen. Im Interview mit financel.de erklären Verwaltungsratspräsident Dr. Cornelius Boersch und Managing Director Frank Steigberger, wie sie sich zukünftig in dem kompetitiven Digital Payments Markt positionieren wollen und was die Analysten zur SANPIPER-Aktie sagen.

Anleihe im Fokus

Jetzt Eyemaxx Anleihe 2018/2023, WKN A2GSSP zeichnen!

Öffentliches Angebot vom 19.04. bis 24.04.2018
Zinssatz: 5,5% p.a.
Laufzeit: 5 Jahre
Halbjährliche Zinszahlung
ISIN/WKN: DE000A2GSSP3 /A2GSSP

GBC im Fokus

Kursziel 2,10 €: Profiteur der steigenden Nachfrage nach Smartphones

UniDevice AG nutzt die weltweit unterschiedlichen Preisniveaus und die unterschiedliche Verfügbarkeit von elektronischen Geräten (hauptsächlich Smartphones) aus. Diesbezüglich hat die Gesellschaft ein internationales Netzwerk an Distributoren und Kunden für sich gewonnen. Für die kommenden Jahre rechnen wir mit einem Anstieg der Erlöse auf über 400 Mio. € (2020e) und einen Anstieg des EBIT auf bis zu 3 Mio. € (2020e). Wir haben ein Kursziel in Höhe von 2,10 € ermittelt. Das Rating lautet KAUFEN.

News im Fokus

Fresenius Medical Care AG & Co. KGaA bestätigt das Wachstumsziel für das Konzernergebnis, passt das Wachstumsziel für den Umsatz für 2018 an und veröffentlicht vorläufige Ergebnisse für das 1. Quartal

22. April 2018, 17:19

Aktuelle Research-Studie

Schweizer Electronic AG

Original-Research: Schweizer Electronic AG (von Montega AG): Kaufen

20. April 2018